Biliary Microbiology and Antimicrobial Treatment Modification in Patients Undergoing Percutaneous Cholecystostomy for Acute Cholecystitis: A Single-Centre Retrospective Cohort Study.

Authors

Berkan Acar, Ali Muhtaroğlu, Selman Alkan, Elif Yılmaz, Serdar Acar, Yavuz Çekiç, Mehmet Yıldız

Published in

International journal of general medicine. Volume 19. Pages 638067. Epub Oct 06, 2026.

Abstract

To describe bile culture yield, organism distribution and antimicrobial treatment modification in patients undergoing percutaneous cholecystostomy (PC) for acute cholecystitis who were unsuitable for early cholecystectomy.
We retrospectively reviewed 84 consecutive patients who underwent PC between December 2021 and December 2025. Index bile cultures were classified as positive, no growth, or not obtained. We analysed organisms, polymicrobial growth, empirical antimicrobial therapy, treatment modification and clinical outcomes by culture status and disease severity.
Bile was cultured in 71 patients (84.5%), and 33 cultures were positive (46.5% of sampled patients; 39.3% of the cohort). Seven positive cultures (21.2%) were polymicrobial. The leading isolates were Escherichia coli (n=13), Enterococcus faecium (n=9) and Klebsiella pneumoniae (n=8). Ceftriaxone plus metronidazole was the most common empirical regimen (52/84, 61.9%). Treatment was modified in 20 patients (23.8%); half of the modified regimens contained a carbapenem. Modification was more frequent among patients requiring intensive care (46.2% versus 13.8%; crude odds ratio [OR] 5.36, 95% confidence interval [CI] 1.83-15.67) and those with Tokyo grade III disease (41.9% versus 13.2%; crude OR 4.75, 95% CI 1.63-13.81). No statistically significant difference was detected between the positive-culture and no-growth groups in treatment modification (24.2% versus 23.7%), in-hospital adverse events (24.2% versus 31.6%), 30-day mortality (12.1% versus 13.2%) or 90-day mortality among evaluable patients (6/32 [18.8%] versus 10/37 [27.0%]).
Bile obtained during PC had a substantial microbiological yield and grew predominantly enteric organisms. Treatment modification was more frequent in clinically severe disease, but no statistically significant difference was detected between positive-culture and no-growth groups. Bile culture should inform a structured reassessment of antimicrobials after source control, rather than automatic treatment escalation.

PMID:
42859667
Bibliographic data and abstract were imported from PubMed on 11 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.